EUPATI held its annual capacity building event for fellows and national platform members and representatives in Berlin on 29 June 2017. The purpose of the meeting was to train and empower participants to share and multiply the knowledge and skills entailed in the EUPATI Expert Training Course and the EUPATI Toolbox to their own patient…Read more
The EUPATI Network of National Platforms held its first general meeting in Berlin on 28 June 2017. Fifteen of the 18 national platforms were represented at the meeting, which was organised and hosted by IPPOSI, the patient organisation umbrella and EUPATI partner in Ireland. In addition to presentations from platform representatives from Germany, Norway, Ireland,…Read more
I participated in the second annual forum of the Scientific Panel for Health organised by the Directorate General for Research and Innovation of the European Union in Brussels on 9 June 2017. Held before a packed room of health research experts from around the EU, the title of the conference was “Health research in a…Read more
Following a long and intense application period, the selection committee for the EUPATI Patient Expert Training Course participants met on 9th May 2017 to decide who of the almost 170 applicants can participate in the course, which will start then in September 2017. Once again, the list of applicants was very impressive, which created an…Read more
Health Technology Assessment is gaining importance in regulatory decisions about the registration and reimbursement of health technologies in a growing number of European states. It is essential to involve patients in this process, and not only because the law requires such involvement in many countries, but also because evidence shows that patients who are informed…Read more
The key assets of EUPATI – the website, the Toolbox, and the Expert Training Course – will be maintained and developed, continuing to educate and empower patients for a more active role as partner in all aspects of medicines research and development.
While this new benefit-risk guideline opens a door to partner with patients for conducting preference studies and to structure patient-focused benefit-risk assessment, we cannot forget that there is a lack of obligation to put these guidelines into effect, and how exactly patient communities and their representatives can get involved in this?
The gap in research related to drug use during pregnancy means that doctors and patients may not have all the facts. Progress in this field is only possible if all stakeholders contribute – starting with all of us, along with the EUPATI Toolkit and website.
Web tools to help you get your content on to the web everything from WYSIWYG editors like KompoZer through Text editors like TextWrangler through to FTP clients like Cyberduck.
The fact of being able to count on a larger number of patients with better knowledge and comprehension of clinical trials principles and issues, can only benefit clinical research.